CMS Proposes Codifying Rules for How It Will Run Drug Negotiations

CMS’s efforts include a change to how and when certain blockbusters get Medicare-set prices

White House Claims a ‘Significant’ Number of Companies Have Elected to Join MFN-in-Medicaid Model

And HHS is taking the next step in transitioning toward a 340B ‘rebate model’

A Key Deadline for Companies Seeking MFN Deals Has Arrived

And Pfizer’s CEO sends a letter to Germany’s leader: ”We are ​reviewing ... certain planned investments in Germany”

Politico Says the U.S. and Germany Are In ‘Secret Talks’ About MFN

And PCMA releases a document that is a master class in finger-pointing

CMS Will Need to Bridge Beyond the ‘Bridge’ Demo to Preserve Long-Term Access to Obesity Meds in Medicare

And I have the numbers on TrumpRx’s web visit numbers for May

It’s All Obesity Today: Drama at ADA, Pricing Implications for Pfizer’s Med, and WSJ on Shrinking Employer Coverage

Plus: ‘Why would you threaten 50% of your revenue if you think you cannot get a reasonable price in the UK or France?’

Supreme Court Addresses ‘Skinny Labeling’ for Generic Drugs

And Pfizer’s Impact Report is out, detailing how the company’s portfolio-wide net price shifted in 2025

An Apex Grab Bag on Value-Based Insurance, Investments in Europe, and Ongoing 340B Battles

TrumpRx Traffic Numbers, Touted by Oz, Appear to Be Falling

And the top of the Fortune 500 list is a who’s-who companies profiting from 340B

Lilly Says Smaller Clinics Have No Problems With 340B Transparency Acts, Even as Big, Profitmaxxing Hospitals Object

The Irony of PCMA Celebrating a PBM Selection Process Won By a Big-PBM Critic

And assessing the unknowns around the plan to reimburse obesity meds in Medicare, which kicks off in a month

Oncology, Long Shielded From Payer Access Challenges, Has Begun to See More Restrictions

And Takeda says that its net prices fell last year

How Will MFN Impact the Pricing of Three Newly Approved Meds?

And advocates for rural 340B providers seek to ensure that urban hospitals don’t abuse 340B provisions intended for rural facilities

Bausch Pulled Out of Medicaid. Then the Price Hikes Began.

And the single most important health-wonk image of the year (so far)

How the Rise of Chinese Biopharma Could Intersect with MFN to Scramble the Global Market and Boost U.S. Drug Prices

The Hidden Middlemen In the TrumpRx Generics Push

The White House Claims TrumpRx Already Saved Americans $400 Million. Is That Right?

Plus an exhaustive look at how 340B came to be

Mark Cuban on Cost Plus Drugs in TrumpRx: ‘The More We Sell, the Lower Our Costs and Then Prices Go’

Generic Meds Now Available on TrumpRx, Powered by Amazon, GoodRx, and Mark Cuban

And the Supreme Court -- for now -- won’t hear drugmaker challenges to Medicare ‘negotiations’

The Six Stories Standing Between You and the Weekend

An Update on One of the More Interesting Price Wars in Biotech

And BMS warns CMS that changes to Medicare negotiation rules could impede innovation for compounds that solve “time toxicity”

The Silence of the Execs: Policy Issues Became (Almost) Invisible in Earnings Calls

And congrats to the ten of you who are still perfect in the Apex “Nobody Knows” prediction contest after the Makary news

Amgen Pulled Repatha From Denmark. A New Forefront Piece Details the MFN Forces at Work.

And Optum Rx says it will overhaul how it charges for PBM services

Trump Links 19,000 Scripts and $15 Million in Savings to Fertility Med Discounts on TrumpRx

The Wall Street Journal on 340B: ‘Government Grift at Its Worst’